Fetal/neonatal allo-immune thrombocytopenia (FNAIT): Past, present, and future

Obstetrical and Gynecological Survey

Volumn 63, Issue 4, 2008, Pages 239-252

  Serrarens Janssen, V M L ^a   Semmekrot, B A ^b   Novotny, V M J ^c   Porcelijn, L ^d,e   Lotgering, F K ^c   Delemarre, F M C ^a   Steegers, E A P ^f  

^a ELKERLIEK HOSPITAL   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Platelet/Leucocyte Serology Department

^e CENTRAL LABORATORY   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; DEXAMETHASONE; HLA ANTIGEN; IMMUNOGLOBULIN; PREDNISOLONE; STEROID; THROMBOCYTE ANTIGEN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; BRAIN HEMORRHAGE; CAUCASIAN; CORDOCENTESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FETAL NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; FEVER; GESTATION PERIOD; HEADACHE; HUMAN; IMMUNOGENETICS; JAPANESE; MALAISE; MYALGIA; NAUSEA; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SCREENING; OLIGOHYDRAMNIOS; POLYMERASE CHAIN REACTION; PRENATAL CARE; PRIMIPARA; RACE; REVIEW; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

ANTIGENS, HUMAN PLATELET; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PLATELET TRANSFUSION; PREGNANCY; PREVALENCE; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 41149169261     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31816412d3     Document Type: Review

References (157)

1. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003;88:F359-F364.
2. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002;16:69-72.
3. Roberts IAG, Murray NA. Neonatal thrombocytopenia: new insights into pathogenesis and implications for clinical management. Curr Opin Pediatr 2001;13:16-21.
4. Menell JS, Bussel JB. Antenatal management of the thrombocytopenias. Clin Perinatol 1994;21:591-614.
5. Davoren A, Curtis BR, Aster RH, et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Immunohematol 2004;44:1220-1225.
6. Lam AH, Shulman LA. Ultrasound in congenital intracranial haemorrhage secondary to isoimmune thrombocytopenia. Pediatr Radiol 1985;15:8-11.
7. Ahya R, Turner ML, Urbaniak SJ. Fetomaternal alloimmune thrombocytopenia. Transfus Apher Sci 2001;25:139-145.
8. Burke Sosa ME. Alloimmune thrombocytopenia in the fetus. J Perinat Neonatal Nurs 2003;17:181-189.
9. Murphy MF, Manley R, Roberts D. Neonatal alloimmune thrombocytopenia. Haematologica 1999;84:110-114.
10. Radder CM, Kanhai HH, de Beaufort AJ, et al. [Evaluation of gradual conversion to a less invasive therapeutic strategy for pregnant women with alloimmune thrombocytopenia in the fetus for prevention of intracranial hemorrhage]. Ned Tijdschr Geneeskd 2000;144:2015-2018.
11. Reznikoff-Etievant MF. Management of alloimmune neonatal and antenatal thrombocytopenia. Vox Sang 1988;55:193-201.
12. Mueller-Eckhardt C, Grubert A, Weisheit M, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1:363-366.
13. Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Haematol 1996;95:21-26.
14. Birchall J, Murphy MF, Kaplan C, et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003;122:275-288.
15. Blanchette VS, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000;13:365-390.
16. Forestier F, Hohlfeld P. Management of fetal and neonatal alloimmune thrombocytopenia. Biol Neonate 1998;74:395-401.
17. Khouzami AN, Kickler TS, Callan NA, et al. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J Matern Fetal Med 1996;5:137-141.
18. Leeuwen van EF, Pel M. Antenatal treatment of alloimmune thrombocytopenia with high dose IgG. Ned Tijdschr Geneeskd 1993;137:416-419.
19. Rothenberger S. Neonatal alloimmune thrombocytopenia. Ther Apher 2002;6:32-35.
20. Murphy MF, Williamson LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using criteria of the UK National Screening Committee. Br J Haematol 2000;111:726-732.
21. Kaplan C, Forestier F, Daffos F, et al. Management of fetal and neonatal alloimmune thrombocytopenia. Transfus Med Rev 1996;10:233-240.
22. Kaplan C. Platelet alloimmunity: the fetal/neonatal alloimmune thrombocytopenia. Vox Sang 2002;83(suppl 1):289-291.
23. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001;41:45-55.
24. Kim HO, Jin Y, Kickler TS, et al. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion 1995;35:863-867.
25. Kluter H, Fehlau K, Panzer S, et al. Rapid typing for human platelet antigen systems-1, -2, -3 and -5 by PCR amplification with sequence-specific primers. Vox Sang 1996;71:121-125.
26. Rozman P, Drabbels J, Schipper RF, et al. Genotyping for human platelet-specific antigens HPA-1, -2, -3, -4 and -5 in the Slovenian population reveals a slightly increased frequency of HPA-1b and HPA-2b as compared to other European populations. Eur J Immunogenet 1999;26:265-269.
27. Gyamfi C, Eddleman KA. Alloimmune thrombocytopenia. Clin Obstet Gynecol 2005;48:897-909.
28. Rozman P. Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation. Transpl Immunol 2002;10:165-181.
29. Noris P, Simsek S, Bruijne-Admiraal LG, et al. Max(a), a new low-frequency platelet-specific antigen localized on glycoprotein IIb, is associated with neonatal alloimmune thrombocytopenia. Blood 1995;86:1019-1026.
30. Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173-1179.
31. von dem Borne AEGKr, de Haas M, Simcek S, et al. Platelet and neutrophil alloantigens in clinical medicine. Vox Sang 1996;70S3:34-40.
32. Mueller-Eckhardt C, Santoso S, Kiefel V. Platelet alloantigens - molecular, genetic, and clinical aspects. Vox Sang 1994;67S3:89-93.
33. Valentin N, Newman PJ. Human platelet alloantigens. Curr Opin Hematol 1994;1:381-387.
34. Cavanagh G, Dunn AN, Chapman CE, et al. HPA genotyping by PCR sequence-specific priming (PCR-SSP): a streamline method for rapid routine investigations. Transfus Med 1997;7:41-45.
35. Newman PJ. Nomenclature of human platelet alloantigens: a problem with the HPA system? Blood 1994;83:1447-1451.
36. von dem Borne AE, Decary F. ICSH/ISBT Working party on platelet serology. Nomenclature of platelet- specific antigens. Vox Sang 1990;58:176.
37. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85:240-245.
38. Kulkarni B, Mohanty D, Ghosh K, et al. Frequency distribution of antigens in the human platelet antigen-1 system in the western Indian population. Transfusion 2002;42:317-320.
39. von dem Borne AEGKr. Nomenclature of human platelet antigens. Blood 1995;85:1409-1410.
40. Randen I, Sorensen K, Killie MK, et al. Rapid and reliable genotyping of human platelet antigen (HPA)-1, -2, - 3, -4, and -5 a/b and Gov a/b by melting curve analysis. Transfusion 2003;43:445-450.
41. Morel-Kopp MC, Blanchard B, Kiefel V, et al. Anti-HPA-4b (anti-Yuk-a) neonatal alloimmune thrombocytopenia: first report in a Caucasian family. Transfus Med 1992;2:273-276.
42. al Sheikh I, Khalifa M, Rahi A, et al. A rare case of neonatal alloimmune thrombocytopenia due to anti-HPA-2b. Ann Saudi Med 1998;18:547-549.
43. Moosmann P, Fauchere JC, Halter J, et al. [Neonatal alloimmune thrombocytopenia due to a rare anti-HPA-1b antibody]. Schweiz Med Wochenschr 2000;130:1734-1737.
44. Glade-Bender J, McFarland JG, Kaplan C, et al. Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001;138:862-867.
45. Kekomaki R, Jouhikainen T, Ollikainen J, et al. A new platelet alloantigen, Tua, on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia in two families. Br J Haematol 1993;83:306-310.
46. Kaplan C, Porcelijn L, Vanlieferinghen P, et al. Anti-HPA-9bw (Max-a) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families. Transfusion 2005;45:1799-1803.
47. Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005;45:353-358.
48. Blanchette VS, Chen L, de Friedberg ZS, et al. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol 1990;74:209-215.
49. Kaplan C, Morel-Kopp MC, Clemenceau S, et al. Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy. Transfus Med 1992;2:265-271.
50. Murphy MF, Williamson LM, Urbaniak SJ. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it? Vox Sang 2002;83(suppl 1):409-416.
51. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen hpa-1a (pi-a1, zw-a) as determined by antenatal screening. Blood 1998;92:2280-2287.
52. Decary F, L'Abbe D, Tremblay L, et al. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med 1991;1:55-62.
53. Jaegtvik S, Husebekk A, Aune B, et al. Neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. Br J Obstet Gynaecol 2000;107:691-694.
54. Doughty HA, Murphy MF, Metcalfe P, et al. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. Br J Haematol 1995;90:321-325.
55. Valentin N, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990;27:73-79.
56. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005;45:1945-1956.
57. Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful? Transfus Med Rev 2000;14:275-280.
58. King KE, Kao KJ, Bray PF, et al. The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue Antigens 1996;47:206-211.
59. De Tar MW, Klohe E, Grosset A, et al. Neonatal alloimmune thrombocytopenia with HLA alloimmunization: case report with immunohematologic and placental findings. Pediatr Dev Pathol 2002;5:200-205.
60. Sasaki M, Yagihashi A, Kobayashi D, et al. Neonatal alloimmune thrombocytopenia due to anti-human leukocyte antigen antibody: a case report. Pediatr Hematol Oncol 2001;18:519-524.
61. Saito S, Ota M, Komatsu Y, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Immunohematol 2003;43:908-917.
62. Moncharmont P, Dubois V, Obegi C, et al. HLA antibodies and neonatal alloimmune thrombocytopenia. Acta Haematol 2004;111:215-220.
63. Skacel PO, Stacey TE, Tidmarsh EF, et al. Maternal alloimmunzation to HLA, platelet and granulocyt-specific antigens during pregnancy: its influence on cord blood granulocyt and platelet counts. Br J Haematol 1989;71:119-123.
64. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfus Med 1994;4:281-292.
65. Bussel JB, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Hematol 1998;11:391-408.
66. Goldman M, Trudel E, Richard L. Report on the Eleventh International Society of Blood Transfusion Platelet Genotyping and Serology Workshop. Vox Sang 2003;85:149-155.
67. Bertrand G, Jallu V, Gouet M, et al. Quantification of human platelet antigen-1a antibodies with monoclonal antibody immobilization of platelet antigens procedure. Transfusion 2005;45:1319-1323.
68. Meyer O, Agaylan A, Borchert H. A simple and practical assay for the antigen-specific detection of platelet antibodies. Transfusion 2006;46:1226-1231.
69. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med 1992;2:181-188.
70. Sainio S, Jarvenpaa AL, Renlund M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000;95:441-446.
71. Bussel JB, Skupski DW, Mcfarland JG. Fetal alloimmune thrombocytopenia: consensus and controversy. J Matern Fetal Med 1996;5:281-292.
72. Berkowitz RL, Bussel JB, Mc Farland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol 2006;195:907-913.
73. Stanworth SJ, Hackett G, Williamson LM. Fetomaternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn 2001;21:418-424.
74. Kuhn MJ, Couch SM, Binstadt DH, et al. Prenatal recognition of central nervous system complications of alloimmune thrombocytopenia. Comput Med Imaging Graph 1992;16:137-142.
75. Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and allo-immune. J Repr Immunol 1997;37:35-61.
76. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988;72:340-343.
77. Bussel JB, Berkowitz RL, McFarland JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988;319:1374-1378.
78. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 1997;14:415-418.
79. Metcalfe P, Allen D, Chapman C, et al. Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens. Br J Haematol 1997;97:204-207.
80. Ohto H, Yamaguchi T, Takeuchi C, et al. Anti-HPA-5b-induced neonatal alloimmune thrombocytopenia: antibody titre as predictor. Br J Haematol 2000;110:223-227.
81. Panzer S. Report on the Tenth International Platelet Genotyping and Serology Workshop on behalf of the International Society of Blood Transfusion. Vox Sang 2001;80:72-78.
82. Teramura G, Slichter SJ. Report on the Sixth International Society of Blood Transfusion Platelet Serology Workshop. Transfusion 1996;36:75-81.
83. Killie MK, Husebekk A, Kjeldsen-Kragh J, et al. Significance of antibody quantification. Vox Sang 2006;91:15. Abstract 51.
84. Husebekk A, Killie MK, Kjeldsen-Kragh J, et al. General overview over screening programs. Vox Sang 2006;91:15. Abstract 49.
85. Bertrand G, Martageix C, Jallu V, et al. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 2006;4:628-637.
86. Killie MK, Kjeldsen-Kragh J, Skogen B, et al. Maternal anti-HPA1a antibody level as predictive value in neonatal alloimmune thrombocytopenic purpura (NAITP). Blood 2004;104. Abstract 2072.
87. Bessos H, Turner M, Urbaniak S. Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia? Immunohematol 2005;21:102-108.
88. Lyou JY, Chen YJ, Hu HY, et al. PCR with sequence-specific primer-based simultaneous genotyping of human platelet antigen-1 to -13w. Transfusion 2002;42:1089-1095.
89. Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: a study of 606 consecutive cases. Am J Obstet Gynecol 1985;153:655-660.
90. Buscaglia M, Ghisoni L, Bellotti M, et al. Percutaneous umbilical blood sampling: indication changes and procedure loss rate in a nine years' experience. Fetal Diagn Ther 1996;11:106-113.
91. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001;185:683-688.
92. Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995;172:475-479.
93. Overton TG, Duncan KR, Jolly M, et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002;186:826-831.
94. Vietor H, Kanhai HHH, Brand A. Induction of additional red cell alloantibodies after intrauterine transfusion. Transfusion 1994;34:970-974.
95. Kornfeld I, Wilson RD, Ballem P, et al. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther 1996;11:210-217.
96. Chaoying M, Junwu G, Chituwo BM. Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants. J Trop Pediatr 1999;45:237-239.
97. Kanhai HHH, Porcelijn L, Zoeren van D, et al. Antenatal care in pregnancies at risk of alloimmune thrombocytopenia: report of 19 cases in 16 families. Eur J Obstet Gynecol Reprod Biol 1996;68:67-73.
98. Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-429.
99. Tiblad E, Olsson I, Petersson K, et al. Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period. Acta Obstet Gynecol Scand 2003;82:803-806.
100. Ino H, Torigoe K, Numata O, et al. A case of neonatal alloimmune thrombocytopenic purpura by anti-HPA-4b with intracranial hemorrhage. J Jpn Pediatr Soc 2000;104:682-685.
101. Peterson JA, Balthazor SM, Curtis BR, et al. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Max-a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 2005;45:1487-1495.
102. Boehlen F, Kaplan C, de Moerloose P. Severe neonatal alloimmune thrombocytopenia due to Anti-HPA-3a. Vox Sang 1998;74:201-204.
103. Proulx C, Filion M, Goldman M, et al. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol 1994;87:813-817.
104. Hoffmann JJML, Janssen WCM, Hedegus von HY. Flow cytometric phenotyping of platelet HPA-1a antigen: donor screening for a case of neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies. Immunohematol 1995;11:125-128.
105. Sainio S, Teramo K, Kekomaki R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med 1999;9:321-330.
106. Rayment R, Brunskill SJ, Stanworth SJ, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia (Review). Cochrane Database Syst Rev 2005;25:CD004226.
107. Yinon Y, Spira M, Solomon O, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol 2006;195:1153-1157.
108. Daffos F, Forestier F, Muller JY, et al. Prenatal treatment of alloimmune thrombocytopenia [letter]. Lancet 1984;632.
109. Bessho T, Ida A, Minagawa K, et al. Effects of maternally administered immunoglobulin on platelet counts of neonates born to mothers with autoimmune thrombocytopenia: reevaluation. Clin Exp Obstet Gynecol 1997;24:53-57.
110. Lucas GF, Hamon M, Carroll S, et al. Effect of IVIgG treatment on fetal platelet count, HPA-1a titre and clinical outcome in a case of feto-maternal alloimmune thrombocytopenia. Br J Obstet Gynaecol 2002;109:1195-1198.
111. Dickinson JE, Marshall LR, Phillips JM, et al. Antenatal diagnosis and management of fetomaternal alloimmune thrombocytopenia. Am J Perinatol 1995;12:333-335.
112. Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol 1997;176:241-253.
113. Lynch L, Bussel JB, McFarland JG, et al. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:67-71.
114. Wenstrom KD, Weiner CP, Williamson RA. Antenatal treatment of fetal alloimmune thrombocytopenia. Obstet Gynecol 1992;80:433-435.
115. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996;174:1414-1423.
116. Gaddipati S, Berkowitz RL, Lembet AA, et al. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol 2001;185:976-980.
117. Berkowitz RL, Kolb A, Mcfarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006;107:91-96.
118. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535-542.
119. Kaplan C, Murphy MF, Kroll H, et al. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids - more questions than answers. European Working Group on FMAIT. Br J Haematol 1998;100:62-65.
120. Ward M, Pauliny J, Lipper EG, et al. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol 2006;23:487-492.
121. Paternoster DM, Cester M, Memmo A, et al. The management of feto-maternal alloimmune thrombocytopenia: report of three cases. J Matern-Fetal Neonatal Med 2006;19:517-520.
122. Whittle MJ. Fetal thrombocytopenia. In: James DK, Steer PJ, eds. High Risk Pregnancy: Management Options. 2000;363-369.
123. Campbell-Lee SA, DeSantis-Parsons D, Sue Shirey R, et al. Neonatal alloimmune thrombocytopenia due to anti-HPA-5b (BR-a). Immunohematol 2003;19:127-131.
124. Akker van den ESA, Oepkes D, Brand A, et al. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia. Br J Obstet Gynaecol 2006;113:781-783.
125. Sia CG, Amigo NC, Harper RG, et al. Failure of cesarean section to prevent intracranial hemorrhage in siblings with isoimmune neonatal thrombocytopenia. Am J Obstet Gynecol 1985;153:79-81.
126. Kaplan C. Fetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis 2006;1:39.
127. Mohanty D, Kulkarni B, Ghosh K, et al. Human platelet specific antigens and their importance. Indian Pediatr 2004;41:797-805.
128. Munizza M, Nance S, Keashen-Schnell MA, et al. Provision of HPA-1a (PLa1)-negative platelets for neonatal alloimmune thrombocytopenia: screening, testing, and transfusion protocol. Immunohematol 1999;15:71-74.
129. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10-23.
130. Allen D, Samol J, Benjamin S, et al. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 2004;14:409-417.
131. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006;107:3761-3763.
132. Chakravorty S, Murray N, Roberts I. Neonatal thrombocytopenia. Early Hum Dev 2005;81:35-41.
133. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang 2003;84:318-825.
134. Simsek S, Christiaens GCLM, Kanhai HHH, et al. Human platelet antigen-1 (Zw) typing of fetuses by analysis of polymerase chain reaction-amplified genomic DNA from amniocytes. Transfus Med 1994;4:15-19.
135. Bennett PR, Warwick R, Vaughan J, et al. Prenatal determination of human platelet antigen type using DNA amplification following amniocentesis. Br J Obstet Gynaecol 1994;101:246-249.
136. Bennett PR, Vaughan J, Handyside A, et al. Potential for pre-implantation determination of human platelet antigen type using DNA amplification: a strategy for prevention of allo-immune thrombocytopenia. Fetal Diagn Ther 1994;9:229-232.
137. Kjeldsen-Kragh J, Killie MK, Skögen B, et al. A screening and intervention program that significantly reduces mortality and serious morbidity associated with grave neonatal alloimmune thrombocytopenia. Vox Sang 2006;91:15. Abstract 50.
138. Akker van den ESA, Oepkes D, Lopriore E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007;114:469-473.
139. Segata M, Chaoui R, Khalek N, et al. Fetal thrombocytopenia secondary to parvovirus infection. Am J Obstet Gynecol 2007;196:61.e1-61.e4.
140. Curties. Immunohematology. Chapter 15, Trombocyten serologie. 2003:258-274.
141. Socher I, Kroll H, Santoso S. Heterogeneity of platelet alloantigens and alloantibodies: new insights into structure and function. Transfus Med Hemother 2006;33:244-253.
142. Covas DT, Biscaro TA, Nasciutti DC, et al. Gene frequencies of the HPA-3 and HPA-5 platelet antigen alleles among the Amerindians. Eur.J. Haematol 2000;65:128-131.
143. b (HPA-4a) antibodies. Brain Dev 1995;17:352-355.
144. Castro V, Origa AF, Annichino-Bizzacchi JM, et al. Frequencies of platelet-specific alloantigen systems 1-5 in three distinct ethnic groups in Brazil. Eur J Immunogenet 1999;26:355-360.
145. Steffensen R, Kaczan E, Varming K, et al. Frequency of platelet-specific alloantigens in a Danish population. Tissue Antigens 1996;48:93-96.
146. Santoso S, Santoso S, Kiefel V, et al. Frequency of platelet-specific antigens among Indonesians. Transfusion 1993;33:739-741.
147. Ferrer G, Muniz-Diaz E, Aluja MP, et al. Gene frequencies of the HPA-1, -2, -3 and -5 platelet antigen alleles in a Berber population. Transfus Med 1998;8:268. Abstract 93.
148. Kupatawintu P, Nathalang O, O-Charoen R, et al. Gene frequencies of the HPA-1 to 6 and Gov human platelet antigens in Thai blood donors. Immunohematol 2005;21:5-9.
149. Chang YW, Mytilineos J, Opelz G, et al. Distribution of human platelet antigens in a Chinese population. Tissue Antigens 1998;51:391-393.
150. Davoren A, McParland P, Barnes CA, et al. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002;55:289-292.
151. Mandelbaum M, Koren D, Eichelberger B, et al. Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen-15 alloimmunization. Vox Sang 2005;89:39-43.
152. Ertel K, Al-Tawil M, Santoso S, et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366-373.
153. Porcelijn L, Huiskes E, Overbeeke M. Rare anti HPA-5a NAIT cases. Vox Sang 2006;91S2. Abstract 55.
154. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995;90:655-660.
155. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, et al. Screening primiparous women and newborns for fetal/ neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 1996;13:423-431.
156. Davoren A, McParland P, Crowley J, et al. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. Br J Obstet Gynaecol 2003;110:492-496.
157. Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenias. Vox Sang 2003;85:326-327.